RxDoctor Payments Data

Barbara Morlan, MD

Family Medicine · Fresno, CANPI 1740241868

Payments from drug & device makers

$13,672in general payments, 2019–2025

Across 790 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Amgen$973
  • Lilly USA, LLC$853
  • Novo Nordisk$848
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$765
  • plus $7K from 41 others

What the payments were for

  • Food & beverage$13,54699%
  • Education$1261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,672 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$138,923
Medicare patients
189
Services billed
2,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$57,563
EliquisApixaban48$42,917
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$29,046
JardianceEmpagliflozin17$26,205
XareltoRivaroxaban15$22,609
JanuviaSitagliptin Phosphate19$20,055
Repatha SureclickEvolocumab12$14,307
MyrbetriqMirabegron12$14,205
PremarinEstrogens, Conjugated17$7,743
VascepaIcosapent Ethyl13$6,321
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen194$6,158
Celecoxib79$6,150
Fenofibrate68$5,304
SynthroidLevothyroxine Sodium36$3,551
Atorvastatin Calcium300$3,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$848$57,56355 claims
PfizerEliquis, Premarin$437$50,66065 claims
GSKTrelegy Ellipta$676$29,04630 claims
Boehringer IngelheimJardiance$525$26,20517 claims
MerckJanuvia$86$20,05519 claims
Astellas Pharma US IncMyrbetriq$189$14,20512 claims
AbbVieSynthroid$2,245$3,55136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →